Leslie William D, MacWilliam Leonard, Lix Lisa, Caetano Patricia, Finlayson Gregory S
Department of Medicine (C5121), St. Boniface General Hospital, 409 Tache Avenue, Winnipeg, R2H 2A6, Canada.
Osteoporos Int. 2005 Jul;16(7):773-82. doi: 10.1007/s00198-004-1756-5. Epub 2004 Oct 2.
Bone density measurement plays a key role in the initial diagnostic assessment of osteoporosis and in targeting pharmacologic therapies. The impact of access to dual-energy X-ray absorptiometry (DXA) on physician prescribing habits is unclear, however. We were able to directly evaluate the change in physician osteoporosis testing and prescribing following introduction of a DXA testing service in a geographic region that had previously had very limited access. This evaluation was conducted in the province of Manitoba, Canada, which has a provincially based bone density testing program and maintains a population-based bone density database that can be linked with administrative health data sources including drug prescriptions. The province of Manitoba was geographically partitioned into the urban and rural health regions serviced by the new program (urban(new )and rural(new)) and the remaining urban and rural health regions which had relatively unchanged DXA access during this period (urban(control) and rural(control)). Regression models of DXA testing rates and osteoporosis prescription rates were created for all older women in these regions. There was a statistically significant increase in bone density testing and BMD-guided osteoporosis treatment in the urban(new) and rural(new) regions following introduction of the DXA testing service, relative to the control regions. Although the overall rate of empiric postfracture and preventive osteoporosis treatment did not show a specific region effect, when analysis was limited to nonhormonal agents there was a significant reduction in preventive and empiric postfracture treatment in some subgroups of women. These results suggest that the local availability of the bone density testing service led to an increase in objective test-guided therapy with some reduction in the use of empiric and preventive strategies and had a neutral effect on overall use of these agents.
骨密度测量在骨质疏松症的初始诊断评估以及靶向药物治疗中起着关键作用。然而,获得双能X线吸收法(DXA)对医生处方习惯的影响尚不清楚。我们能够直接评估在一个此前获得DXA检测服务机会非常有限的地理区域引入该检测服务后,医生对骨质疏松症检测和处方的变化情况。这项评估在加拿大曼尼托巴省进行,该省有一个基于省级的骨密度检测项目,并维护一个基于人群的骨密度数据库,该数据库可与包括药物处方在内的行政健康数据源相链接。曼尼托巴省在地理上被划分为由新计划服务的城市和农村健康区域(城市(新)和农村(新))以及在此期间DXA获取情况相对未变的其余城市和农村健康区域(城市(对照)和农村(对照))。为这些区域的所有老年女性建立了DXA检测率和骨质疏松症处方率的回归模型。与对照区域相比,在引入DXA检测服务后,城市(新)和农村(新)区域的骨密度检测以及基于骨密度指导的骨质疏松症治疗有统计学上的显著增加。尽管骨折后经验性和预防性骨质疏松症治疗的总体发生率未显示出特定的区域效应,但当分析仅限于非激素类药物时,某些女性亚组的预防性和骨折后经验性治疗有显著减少。这些结果表明,骨密度检测服务的本地可及性导致客观检测指导治疗增加,经验性和预防性策略的使用有所减少,并且对这些药物的总体使用有中性影响。